These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 8357285)
1. Early administration of heme arginate for acute porphyric attacks. Mustajoki P; Nordmann Y Arch Intern Med; 1993 Sep; 153(17):2004-8. PubMed ID: 8357285 [TBL] [Abstract][Full Text] [Related]
2. [Acute attacks of hepatic porphyria: specific treatment with heme arginate]. Nordmann Y; Deybach JC Ann Med Interne (Paris); 1993; 144(3):165-7. PubMed ID: 8368699 [TBL] [Abstract][Full Text] [Related]
3. Plasma porphobilinogen as a sensitive biomarker to monitor the clinical and therapeutic course of acute intermittent porphyria attacks. Sardh E; Harper P; Andersson DE; Floderus Y Eur J Intern Med; 2009 Mar; 20(2):201-7. PubMed ID: 19327613 [TBL] [Abstract][Full Text] [Related]
4. An analysis of 112 acute porphyric attacks in Cape Town, South Africa: Evidence that acute intermittent porphyria and variegate porphyria differ in susceptibility and severity. Hift RJ; Meissner PN Medicine (Baltimore); 2005 Jan; 84(1):48-60. PubMed ID: 15643299 [TBL] [Abstract][Full Text] [Related]
5. Hemodialysis: a therapeutic option for severe attacks of acute intermittent porphyria in developing countries. Prabahar MR; Manorajan R; Sathiyakumar D; Soundararajan P; Jayakumar M Hemodial Int; 2008 Jan; 12(1):34-8. PubMed ID: 18271838 [TBL] [Abstract][Full Text] [Related]
6. Heme arginate (Normosang) in the treatment of attacks of acute hepatic porphyrias. Kostrzewska E; Gregor A; Tarczyńska-Nosal S Mater Med Pol; 1991; 23(4):259-62. PubMed ID: 1842231 [TBL] [Abstract][Full Text] [Related]
7. Intravenous heme-albumin in acute intermittent porphyria: evidence for repletion of hepatic hemoproteins and regulatory heme pools. Bonkovsky HL; Healey JF; Lourie AN; Gerron GG Am J Gastroenterol; 1991 Aug; 86(8):1050-6. PubMed ID: 1713408 [TBL] [Abstract][Full Text] [Related]
8. Medical and financial burden of acute intermittent porphyria. Neeleman RA; Wagenmakers MAEM; Koole-Lesuis RH; Mijnhout GS; Wilson JHP; Friesema ECH; Langendonk JG J Inherit Metab Dis; 2018 Sep; 41(5):809-817. PubMed ID: 29675607 [TBL] [Abstract][Full Text] [Related]
9. Mortality in patients with acute intermittent porphyria requiring hospitalization: a United States case series. Jeans JB; Savik K; Gross CR; Weimer MK; Bossenmaier IC; Pierach CA; Bloomer JR Am J Med Genet; 1996 Nov; 65(4):269-73. PubMed ID: 8923933 [TBL] [Abstract][Full Text] [Related]
10. Controlled trial of haem arginate in acute hepatic porphyria. Herrick AL; McColl KE; Moore MR; Cook A; Goldberg A Lancet; 1989 Jun; 1(8650):1295-7. PubMed ID: 2566827 [TBL] [Abstract][Full Text] [Related]
11. Porphyric neuropathy: prevention of progression using haeme-arginate. Muthane UB; Vengamma B; Bharathi KC; Mamatha P J Intern Med; 1993 Dec; 234(6):611-3. PubMed ID: 8258754 [TBL] [Abstract][Full Text] [Related]
17. Haem arginate as effective maintenance therapy for hereditary coproporphyria. Ma E; Mar V; Varigos G; Nicoll A; Ross G Australas J Dermatol; 2011 May; 52(2):135-8. PubMed ID: 21605099 [TBL] [Abstract][Full Text] [Related]
18. Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases. Kauppinen R; Mustajoki P Medicine (Baltimore); 1992 Jan; 71(1):1-13. PubMed ID: 1549056 [TBL] [Abstract][Full Text] [Related]
19. [Treatment of acute intermittent porphyria. The first use of Heme-arginate in Czechoslovakia]. Kordac V; Martásek P Cas Lek Cesk; 1987 Jul; 126(30):944-7. PubMed ID: 3652151 [No Abstract] [Full Text] [Related]